Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas

Abstract

Activating mutations within the epidermal growth factor (EGFR) tyrosine kinase domain identify non-small cell lung cancer patients with improved clinical response to tyrosine kinase inhibitor therapy. Recently, we identified two EGFR mutations in a cohort of 25 salivary gland carcinomas (SGCs) by screening the tumour samples for the both most common hotspot mutations in exons 19 and 21 by allele-specific PCR. Here, we present a comprehensive sequencing analysis of the entire critical EGFR tyrosine kinase domain in 65 SGC of the main histopathological types. We found EGFR mutations in the tyrosine kinase domain to be a rare event in SGCs. No additional mutations other than the two known exon 19 deletions (c.2235_2249del15) in a mucoepidermoid carcinoma and an adenoid cystic carcinoma have been detected. Other putative predictive markers for EGFR-targeted therapy in SGCs might be relevant and should be investigated.

Malignant salivary gland neoplasms account for <0.5% of all malignancies and approximately 3–5% of all head-and-neck cancers (Milano et al, 2007). Salivary gland carcinomas (SGCs) represent a histopathologically heterogeneous group with different biological behaviour and clinical outcome. The main histopathologic types are (1) mucoepidermoid carcinoma that represents 29–34% of malignant tumours; (2) adenoid cystic carcinoma (ACC; 20%); (3) adenocarcinoma including acinic cell carcinoma; and (4) salivary duct carcinoma (Milano et al, 2007). Progress in understanding the cell biology of SGCs and detecting vulnerable molecular pathways may lead to the development of new targeted therapy options. Epidermal growth factor (EGFR; also known as ErbB1) is considered a possible key pathway for therapeutic molecules. Overexpression of EGFR has been shown in both salivary ACC and non-ACC (Agulnik et al, 2007; Ettl et al, 2008), and these findings have provided the motivation for trials with EGFR inhibitor-based therapies. Anti-EGFR agents include (1) monoclonal antibodies (cetuximab or erbitux, panitumumab), which block the binding of natural EGFR ligands, such as EGF or TGF-α, resulting in inhibition of downstream signal transduction pathways and (2) small molecule tyrosine kinase inhibitors (TKIs), which act by binding the ATP pocket within the kinase domain of the EGFR and impairing its catalytic activity (gefitinib, erlotinib and lapatinib). Cetuximab (erbitux) has been tested in two phase II studies in patients with recurrent and/or metastatic SGCs including mainly ACC, a cancer with generally poor outcome. In 50% of patients, clinical benefit (i.e., response or stable disease for 6 months) could be achieved (Milano et al, 2007; Locati et al, 2008). Gefitinib was associated with a 53% stable disease rate (10/19) in ACC, but had no effects in patients with salivary duct tumours and mucoepidermoid cancer (Glisson et al, 2005). Lapatinib, inhibiting ErbB1 and ErbB2 tyrosine kinases, was studied in a phase II trial and stabilized disease for greater than 6 months in 47% of ACC patients (Agulnik et al, 2007).

Earlier studies (Lynch et al, 2004; Paez et al, 2004; Eberhard et al, 2005; Riely et al, 2006a) had identified a subset of lung cancer patients with rapid and durable clinical responses to EGFR TKIs and found an underlying association between activating mutations in the EGFR tyrosine kinase domain and therapy response. Since then, four validated drug-sensitising mutations and three kinase domain mutations associated with drug resistance have been reported (Riely et al, 2006b). As with lung adenocarcinomas, mutations in the EGFR tyrosine kinase domain may be associated with clinical efficacy of EGFR inhibitors in the treatment of SGCs. Recently, we identified a mucoepidermoid carcinoma and an ACC with a TKI-sensitising EGFR exon 19 deletion mutation by screening EGFR exons 19 and 21 for the two most common hotspot mutations by an allele-specific PCR test (Dahse and Kosmehl, 2008).

The aim of this study was to sequence the entire critical EGFR tyrosine kinase domain and to determine how frequently drug-sensitising and drug-resistant EGFR mutations might occur in a large cohort of SGCs of the main histopathological types.

Materials and methods

Surgically removed formalin-fixed tumour samples were obtained from 65 patients (35 males and 30 females with a median age at diagnosis of 55 years) treated with the histopathological diagnosis of an SGC according to the WHO classification (Barnes et al, 2005). All patients received surgery and in selected cases of postoperative radiation therapy. Epidermal growth factor receptor-targeted therapy was not applied. The study cohort consisted of ACC (n=25), mucoepidermoid carcinoma (n=10), myoepithelial carcinoma (n=8), acinic cell carcinoma (n=12) and adenocarcinoma ex pleomorphic adenoma (n=10).

Deoxyribonucleic acid was isolated from microdissected tumour areas using the QIAamp DNA Mini Kit (Qiagen GmbH, Hilden, Germany).

Epidermal growth factor exons 18, 19, 20 and 21 were amplified by nested PCR using primers described previously (Eberhard et al, 2005). Polymerase chain reaction products were purified with the QIAquick PCR Purification Kit (Qiagen GmbH). Genomic sequencing was performed using fluorescent dye-terminator chemistry and the primer M13F: 5′-TGTAAAACGACGGCCAGT-3′ (MWG Biotech, Martinsried, Germany). The reported mutations were scored as reproducible, having been identified in two independent PCR amplifications and by M13 sequencing in both directions (M13R: 5′-CAGGAAACAGCTATGACC-3′).

The numbering of the EGFR nucleotide and amino acid positions was according RefSeq sequences NM 005228.3 and NP 005219.2, respectively.

This study was conducted in accordance with the principles of the Declaration of Helsinki, as adopted by the 29th World Medical Assembly, Helsinki, Finland.

Results

Sequencing analysis of exons 18–21 of the EGFR tyrosine kinase domain in 65 SGCs revealed two cases (3.1, 95% exact confidence limit: 0.5–1.2) with a heterozygous exon 19 deletion mutation. The two exon 19 E746_A750 deletions (both of them were variant c.2235_2249del15) were identified in a mucoepidermoid carcinoma of the left parotid gland grade 2 (54-year-old female patient, smoker), and in an ACC of solid type of the right parotid gland (69-year-old male patient, non-smoker). The female patient with the mucoepidermoid carcinoma was treated with surgery and postoperative radiation, the male patient with ACC by surgical tumour resection alone. Both patients had a favourable course of their cancer disease with no manifestation of recurrences (follow-up time 24 months).

In exon 20, an SNP c.2607 G>A (p.Q787Q) was detected in 29 out of 65 tumour samples (44.6%, 95% exact confidence limit: 32.5–57.4).

Discussion

Somatic mutations in the EGFR kinase domain are found in a subset of lung adenocarcinomas and are associated with sensitivity to TKI (point mutations G719A/C in exon 18, L858R and L861Q in exon 21 and in-frame deletions at position 745 of exon 19). Three kinase domain mutations are associated with drug resistance: D761Y in exon 19, T790M in exon 20 and an exon 20 insertion (D770N771insNPG). The exon 19 deletions and L858R in exon 21 represent 85–90% of EGFR mutations in non-small cell lung cancer. In two recent trials in advanced non-small cell lung cancer, therapy with gefitinib administered in a genotype-directed fashion to patients harbouring EGFR mutations resulted in very favourable clinical outcomes with good tolerance (Sequist et al, 2008; Tamura et al, 2008).

Given the comparable embryonal tissue origin between lung adenocarcinoma and SGCs and the potential for genotype-directed trials of EGFR inhibitors, we undertook a comprehensive mutational analysis of EGFR in SGCs. We found EGFR mutations in the tyrosine kinase domain to be a rare event in SGCs of Caucasian origin. Whereas approximately 10–30% of lung carcinoma contain EGFR mutations (Mitsudomi and Yatabe, 2007), they seem to be seldom acquired in the cancers of other organs (EGFR mutation database:http://www.cityofhope.org/cmdl/egfr%5Fdb/).

Both of the mutations detected in our cohort were found in histopathological types (mucoepidermoid carcinoma and ACC), which also occur in the lung. In a recently published study, in two out of five (40%) of mucoepidermoid carcinoma of lung (which originate from minor salivary glands of the tracheobrochial tree), the L858R mutation was detected and all five patients well responded to TKI therapy independent of the mutation status (Han et al, 2008). In contrast, in another study with 24 cases of adenoid cystic and mucoepidermoid salivary gland-type lung carcinomas, EGFR protein expression was found in 91%, but no mutation was detected in exons 18–21 of the EGFR gene (Macarenco et al, 2008). In head-and-neck cancers, in which about 10% of cases showed responses to gefitinib, no mutations were noted in a US study, but 7% of tumours of Asian origin were found to harbour such mutations (Cohen et al, 2005; Lee et al, 2005).

In conclusion, drug-sensitising EGFR mutations are rather rare in SGCs and seem to be mainly found in a few mucoepidermoid and ACC. Taking into consideration the encouraging relative high number of responding SGC patients (particularly ACC patients with poor prognosis) who achieved stable disease after cetuximab treatment in the phase II trials and the apparently low incidence of drug-sensitising EGFR mutations, it would appear that also other biological factors than EGFR tyrosine kinase mutations might influence the therapy response. The underlying mechanisms of response to targeted therapies are complex and still not fully elucidated. Investigating those mechanisms and the mutation status of proteins in the cascade downstream of EGFR might identify further predictive markers for EGFR-targeted therapy in SGCs and would allow the selection of patients for a successful treatment.